These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 10576658)

  • 1. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
    Schmidt-Wolf IG; Finke S; Trojaneck B; Denkena A; Lefterova P; Schwella N; Heuft HG; Prange G; Korte M; Takeya M; Dorbic T; Neubauer A; Wittig B; Huhn D
    Br J Cancer; 1999 Nov; 81(6):1009-16. PubMed ID: 10576658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene.
    Finke S; Trojaneck B; Lefterova P; Csipai M; Wagner E; Kircheis R; Neubauer A; Huhn D; Wittig B; Schmidt-Wolf IG
    Gene Ther; 1998 Jan; 5(1):31-9. PubMed ID: 9536262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine-induced killer cells showing multidrug resistance and remaining cytotoxic activity to tumor cells after transfected with mdr1 cDNA.
    Li HF; Yang YH; Shi YJ; Wang YQ; Zhu P
    Chin Med J (Engl); 2004 Sep; 117(9):1348-52. PubMed ID: 15377427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
    J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
    Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody.
    Kim JA; Bresler HS; Martin EW; Aldrich W; Heffelfinger M; Triozzi PL
    Cancer; 1999 Jul; 86(1):22-30. PubMed ID: 10391559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Identification of immunological effector cells after autologous cytokine-induced killer cells treatment and its clinical implication in hepatocellular carcinoma patients].
    Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Liu JC; Fan ZP; Li HW; Mu JS; Wang FS
    Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2049-53. PubMed ID: 14703414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
    Galanis E; Burch PA; Richardson RL; Lewis B; Pitot HC; Frytak S; Spier C; Akporiaye ET; Peethambaram PP; Kaur JS; Okuno SH; Unni KK; Rubin J
    Cancer; 2004 Dec; 101(11):2557-66. PubMed ID: 15517589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study.
    Sun Y; Jurgovsky K; Möller P; Alijagic S; Dorbic T; Georgieva J; Wittig B; Schadendorf D
    Gene Ther; 1998 Apr; 5(4):481-90. PubMed ID: 9614572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
    Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
    Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
    Favrot MC; Combaret V; Negrier S; Philip I; Thiesse P; Freydel C; Bijmann JT; Franks CR; Mercatello A; Philip T
    J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
    Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical observation on adoptive immunotherapy with autologous cytokine-induced killer cells for advanced malignant tumor].
    Chen FX; Liu JQ; Zhang NZ; Gong XJ; Zhang GL; Xu YM; Zhou ZH; Wang T; Huang J
    Ai Zheng; 2002 Jul; 21(7):797-801. PubMed ID: 12479111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
    Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS
    Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
    Thompson JA; Figlin RA; Sifri-Steele C; Berenson RJ; Frohlich MW
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3562-70. PubMed ID: 14506142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.